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Background: The over 100 serotypes of human rhinoviruses (HRV) are major
causative agents of the common cold in humans. These HRVs can be roughly
divided into a major and minor group according to their cellular receptors. They
can also be divided into two antiviral groups, A and B, based on their sensitivity
to different capsid-binding antiviral compounds. The crystal structures of HRV14
and HRV16, major-receptor group rhinoviruses, as well as HRV1A, a minor-
receptor group rhinovirus, were determined previously. Sequence comparisons
had shown that HRV14 seemed to be an outlier among rhinoviruses.
Furthermore, HRV14 was the only virus with no cellular ‘pocket factor’ in a
hydrophobic pocket which is targeted by many capsid-binding antiviral
compounds and is thought to regulate viral stability. HRV3, another major-
receptor group virus, was chosen for study because it is one of a subset of
serotypes that best represents the drug sensitivity of most rhinovirus serotypes.
Both HRV3 and HRV14 belong to antiviral group A, while HRV16 and HRV1A
belong to antiviral group B.
Results: Surprisingly, HRV3 was found to be very similar to HRV14 in sequence
and structure. Like HRV14, crystallized HRV3 also has no bound pocket factor.
The structure of HRV3 complexed with an antiviral compound, WIN56291, was
also determined and found to be similar to the same antiviral compound
complexed with HRV14.
Conclusions: The amino-acid sequence and structural similarity between
HRV3 and HRV14 suggests that rhinoviruses in the same antiviral group have
similar amino-acid sequences and structures. The similar amino-acid
composition in the pocket region and the viral protein VP1 N termini in all
known group B HRV sequences suggests that these viruses may all contain
pocket factors and ordered N-terminal amphipathic helices in VP1. Both of
these factors contribute to viral stability, which is consistent with the
observations that group B rhinoviruses have a higher chance of successful
transmission from one host to another and is a possible explanation for the
observed higher pathogenicity of these rhinoviruses.
Introduction
Human rhinoviruses (HRV) are a genus of the picornavirus
family and are the major causative agent of common colds.
There are over 100 different serotypes, which can be
divided into at least two groups [1]. The majority of HRVs
(the major-receptor group viruses) use intercellular adhe-
sion molecule-1 (ICAM-1) as a receptor [2,3] for cell
attachment and entry. The remaining rhinoviruses (the
minor-receptor group viruses), except for HRV87 [4], can
utilize low density lipoprotein receptor molecules [5].
The single-stranded (+) RNA genome of HRVs is about
7.2kb in length and is encapsidated by a protein shell that
has pseudo T=3 icosahedral symmetry. The diameter of
the virus is about 300Å, and the molecular weight is
approximately 8.5×106 Da. The RNA genome directs the
synthesis of a polyprotein, which is subsequently cleaved
into capsid proteins and nonstructural proteins. The viral
capsid is made of 60 copies each of viral proteins VP1–VP4.
VP1, VP2 and VP3 each have a molecular weight of about
30kDa; VP4 is a 7kDa small protein that lines the internal
surface of the capsid. The crystal structures of HRV14 [6]
and HRV16 [7], both belonging to the major-receptor
group of rhinoviruses, and of HRV1A [8], belonging to the
minor-receptor group of rhinoviruses, have been deter-
mined previously. Each of the viral proteins VP1, VP2 and
VP3 is folded into an eight-stranded (bB–bI) antiparallel b-
barrel motif which has a well conserved topology among
picornaviruses. The eight b strands form two opposing
sheets ‘BIDG’ and ‘CHEF’. The BIDG sheet faces mostly
towards the viral interior, whereas the CHEF sheet is more
exposed on the exterior of the viral surface. The barrel has
a wedge shape, with the BC, HI, DE and FG loops forming
the narrow end that points toward the icosahedral fivefold
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axes in the case of VP1 or towards the quasi-sixfold axes in
the case of VP2 and VP3.
There is a ‘canyon’ with a depth of approximately 15Å
surrounding each of the icosahedral fivefold axes (Fig. 1).
The floor of the canyon is mainly made of the GH loop in
VP1. The ‘north’ rim of the canyon, closer to the viral five-
fold axis, is formed exclusively by VP1. The GH loop in
VP1, together with the C termini of VP1 and VP3, form
the ‘south’ rim of the canyon, further away from the viral
fivefold axis. Residues lining the canyon floor are more
conserved than are other surface residues [9,10]. It was
proposed that the cellular receptor would bind to residues
on the canyon floor. These residues are inaccessible to
antibodies due to steric hindrance and would, therefore,
allow the virus to escape host immune surveillance [6,11].
This hypothesis was supported by site-directed mutagene-
sis of residues on the canyon floor [12] and was confirmed
by cryoelectron microscopy of HRV16 complexed with
soluble ICAM-1 [13]. Furthermore, antibody molecules
were demonstrated to bind on the canyon rim by analyzing
antibody neutralizing escape mutations [14] and by cryo-
electron microscopy of HRV14 complexed with neutraliz-
ing antibodies [15]. The escape mutations were clustered
into four areas, the neutralizing immunogenic (NIm) sites
IA, IB, II and III.
There is a hydrophobic pocket, between the BIDG and
CHEF sheets of VP1, underneath the canyon (Fig. 1). A
series of antiviral compounds designed by the former
Sterling-Winthrop Pharmaceutical Company (WIN com-
pounds) and other pharmaceutical companies bind into
this pocket [16–18] and cause conformational changes of
up to 4 Å for some Ca atoms in HRV14. However, in
HRV16 and HRV1A, these compounds displace a previ-
ously resident ‘pocket factor’ (see below) and, hence,
cause only small conformational changes. The WIN com-
pounds can inhibit viral uncoating [16] and, in some cases,
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Diagrammatic view of picornavirus with enlargement of one
icosahedral asymmetric unit showing the outline of the canyon and the
entrance to the antiviral-binding pocket. The protomeric assembly unit
(which differs from the geometric definition of the asymmetric unit) is
shown in heavy outline on the icosahedron. The arrow B shows the
direction of view used in Figure 7. (The figure was adapted from
Oliveira et al. [7], with permission.)
also attachment to cells [19]. Rhinoviruses have been clas-
sified into antiviral groups A and B, based on their sensi-
tivity to 15 antiviral compounds [20]. The minor-receptor
group viruses all belong to antiviral group B (for example,
HRV1A); however, the major-receptor group HRVs are
scattered among antiviral groups A and B (for example,
HRV14 and HRV3 belong to group A, whereas HRV16
belongs to group B). Viruses in group A are more sensitive
to long antiviral compounds, whereas viruses in group B
have greater sensitivity to short compounds.
In native HRV1A and HRV16, the pocket in VP1 is filled
with electron density interpreted as either an eight-
carbon [18] or twelve-carbon ([7]; AT Hadfield, personal
communication) fatty acid (the ‘pocket factor’), based on
its shape, the hydrophobic nature of the pocket and the
polar environment at the pocket entrance. In HRV14,
however, this pocket is empty. Similar pocket factors
were observed in some other picornavirus structures, 
for example, a putative sphingosine or palmitate molecule
in polioviruses (Mahoney type 1, Sabin type 3 and a
chimeric type 2) [21–23], myristic acid in bovine
enterovirus [24] and a putative palmitate molecule in cox-
sackievirus B3 [25]. No data are available as to the exact
chemical identity of the pocket factor, although there 
is evidence for binding of myristic acid to bovine
enterovirus. When WIN compounds or shorter WIN com-
pound fragments, mimicking the pocket factor, bind into
this pocket, they stabilize the virus to acidification [26]
and heating [27–29]. It has been proposed that the pocket
factor stabilizes the virion for transport between hosts,
while it is displaced by the receptor during cell entry 
in preparation for uncoating [7,11]. This is equivalent to
stabilizing proteins by filling hydrophobic holes with
hydrophobic residues or compounds [30–32].
When rhinoviruses bind to cells, they are first converted to
‘A’ (‘altered’) particles which lack VP4 [33–35]. Subse-
quently, the A particles lose RNA and form empty parti-
cles. The A particles are hydrophobic [35,36], and their
formation in polioviruses is associated with the external-
ization of the N terminus of VP1 [37].
The initial motivation for studying HRV3 was that this
virus was used by the Sterling-Winthrop Pharmaceutical
Company as one of a subset of serotypes that best repre-
sents the drug sensitivity of most rhinovirus serotypes
[38]. We report here the nucleotide sequence determina-
tion of the HRV3 genome corresponding to the capsid
proteins, the structure determination of HRV3 at 3.0 Å 
resolution and the structure determination of the complex
of HRV3 with antiviral compound WIN56291. The same
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Figure 2
The BC loop in VP1. (a) HRV3 electron
density for the BC loop of VP1 (residues
1085–1098). The structure in HRV3 is shown
with a thick line and that for HRV14 is shown
with a thin line. (b) Different lengths and
conformations of the BC loop of VP1 in HRV3
(purple), HRV14 (red), HRV16 (green), HRV1A
(yellow), polio1 (black) and polio3 (blue).
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compound had previously been studied when complexed
to HRV14, HRV16 and HRV1A [7,18].
Results and discussion
Quality of the HRV3 electron-density map
The good quality of the HRV3 electron-density map at
3.0Å resolution was indicated by the differentiation of
residues that differed between HRV3 and HRV14 (Fig. 2a).
Because of the presence of the noncrystallographic symme-
try, a true measure of error in the electron density can be
computed as the root mean square (rms) standard error, s,
between noncrystallographic symmetry related electron
density. The value of s found in this way was about one-
third of the electron density rms deviation from zero. The
maximum density for most of the main-chain atoms was
around 10s above zero, the mean level of the map.
However, residues 1216–1223 (amino acid sequence
numbers start with 1000, 2000, 3000 and 4000 for VP1, VP2,
VP3 and VP4, respectively), in the GH loop of VP1, had
density weaker than 6s above the mean level of the map
and their side-chain density was also weak and diffuse,
indicating the flexibility of the GH loop in HRV3. The
N-terminal residues 1001–1015, 2001–2007 and 4001–4025
could not be seen at any level. Uninterpretable, noise 
features started to appear at about 2s above the mean level
of the map.
The antigenic surface
Although the amino-acid sequences of HRV14 and HRV3
have considerable similarity (88% amino-acid sequence
identity in the structural proteins), they are serologically
distinguishable. Consequently, there should be some dif-
ference in the amino acids on the viral surface, especially
those which represent the four primary antigenic epitopes,
namely NIm IA, IB, II and III in HRV14. Out of the 106
residues that differ between HRV3 and HRV14, 60 are
located on the viral surface. Furthermore, the antigenic
BC loop of VP1, which forms much of the NIm IA
epitope, is particularly variable in length and sequence
among rhinoviruses and polioviruses (Fig. 2b). It has been
used extensively for making chimeric viruses and altering
the serological types of polioviruses [23,39–44]. Although
there is little difference in conformation of this loop
between HRV3 and HRV14 (Fig. 2a), the amino-acid
sequence is rather different: 
HRV3: K N A A G L D N H R K E G L
HRV14: K D A T G I D N H R E A K L
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Diagrammatic view of the canyon (arbitrarily demarcated by a 146 Å
radial distance from the viral center) and the Fab17 footprint (shaded
area; top panel). Also shown are enlarged views of residues in the
Fab17 footprint on HRV14 (left panel) and their corresponding
residues in HRV3 (right panel). Charged residues, proposed to be
important in the antibody–virus interaction, are shown as shaded
areas in the left panel. Residues in HRV3 which differ from those in
HRV14 are shown as shaded areas in the right panel.
The NIm site IA and its area of interaction with a neutraliz-
ing antibody has been mapped in a study of the complex of
the antibody fragment Fab17 with HRV14 [15]. The com-
plementarity of charge between Fab17 and viral surfaces
was proposed to be a major contribution to the binding
energy [15]. Some of the residues involved in HRV14–anti-
body charge interaction have changed in HRV3 (Fig. 3),
thus altering the requirements for neutralizing antibodies
binding to epitope IA.
The other three NIm sites, IB, II and III, have not been
studied as carefully as IA. The only available information
relates to escape mutations in HRV14 to neutralizing anti-
bodies. Although the mutated residues identify a central
portion of the antigenic epitope, the extent of the surface
covered by the bound antibody remains unknown. Never-
theless, comparison of the escape mutations in HRV14
with the sequence of HRV3 shows that HRV3 has changes
in each of the four NIm sites and that, in many cases,
HRV3 has the sequence of an escape mutation (Table 1).
This demonstrates that the set of neutralizing antibodies
for HRV3 is non-overlapping with that for HRV14.
VP4 and the N-terminal end of VP1
The differences between rhinoviruses are mainly located
on the external surface loops or the internal capsid sur-
faces, in particular the conformation of VP4 and the N ter-
minus of VP1 (Table 2). The structure of VP4 and the
N terminus of VP1 can be roughly divided into three types
represented by HRV3 or HRV14, by HRV1A or HRV16,
and by polio1 or polio3 (Fig. 4a). Of particular interest is
the disordered N-terminal end of VP1 in HRV3 or HRV14
compared with the amphipathic helix that occurs in
HRV1A or HRV16, or the strand of a b sheet that occurs 
in polio1 or polio3. The hydrophobic side of the helix in
HRV16 mainly interacts with the ten-stranded b barrel
formed by the N termini of VP4. The hydrophilic side of
this helix faces the viral interior. The preference for the N
termini of VP1 to form an amphipathic helix in HRV16
and HRV1A is apparent in helical wheel plots (Fig. 4b).
The amphipathic character of this region is disrupted to a
certain extent in HRV14, HRV3 (Fig. 4b), polio1 and
polio3 [37]. The hydrophobic characteristics of the VP1 N-
terminal residues are well conserved among all antiviral
group B rhinoviruses such as HRV16 and HRV1A (Fig. 4c),
suggesting that these viruses may all form N-terminal
amphipathic helices in VP1.
The N terminus of VP4 forms two b strands of a ten-
stranded b barrel surrounding the fivefold axis in HRV16
or forms two b strands of a three-stranded b sheet in
polio1 and polio3 (Fig. 4a). The N terminus of VP4 is
disordered in HRV1A, HRV14 and HRV3. However,
there is density in HRV3 at a 2 s level, which might cor-
respond to the extreme N terminus of VP4 (possibly
residues 4003–4006) and form a b sheet with residues
4026–4029. Similar density features are also visible at low
contour levels in the electron density of HRV1A and
HRV14, although they are less obvious than that in
HRV3. The N terminus of VP4 is myristylated in many
picornaviruses and may play a role in viral assembly by
stabilizing the pentamers and in viral penetration of
membranes [45,46]. The myristate is visible in the elec-
tron density of HRV16 (AT Hadfield, RZ and MGR,
unpublished results), poliovirus [22] and coxsackievirus
B3 [25]. There is density which might correspond to the
myristate attached to VP4 in HRV1A [8].
The ambivalence between disordered (HRV14 and
HRV3) and ordered (HRV16 and to some extent HRV1A)
helical structures in the N-terminal residues of VP1 may
represent different points of equilibrium in the capsid
assembly, giving the virion different degrees of stability
prior to cell entry and disassembly. The binding of the
N-terminal helix in VP1 to VP4 in HRV16 may increase
the stability of the virus as it would stabilize the myristate
cluster and hinder the ejection of VP4 on binding to cells
or soluble ICAM-1. This is consistent with the greater
stability of HRV16 compared with HRV3 and HRV14
[35]. In this case, the hydrophobic contacts between the
VP1 helix and VP4 restrain the release of VP4 from 
the virion. Even more dramatically, when the C-terminal
end of VP4 is covalently attached to the N-terminal end
of VP2 in a maturation cleavage deficient mutant, the
release of VP4 is inhibited, resulting in non-infectious
particles [47].
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Table 1
Escape mutations in the HRV14 NIm sites and their
corresponding residues in HRV3.
NIm sites Residues Escape mutations Corresponding
in HRV14 residues in HRV3
IA 1091 D A E G H N V Y D
1095 E G K K†
IB 1083 Q H K
1085 K N K
1138 D E G E†
1139 S P A
II 2158 S F T
2159 A V V†
2161 E D V* D* K V†
2162 V M A* A†
1210 E D* D†
2136 E G E
III 3072 N I H
3075 R G K M R
3078 E K V E
1287 K I K
3203 G D G
*Mutants with double mutations: V2161 and A2162; D2161 and
D1210. †Residues in HRV3 that are identical to the escape mutations
in HRV14.
Ca2+ binding
The DE loop of VP1 is involved in the interaction with a
putative Ca2+ ion on the viral fivefold axis in all analyzed
rhinoviruses [48]. A density peak, about three-fifths of the
height of the protein density, is located at the putative Ca2+
ion position in HRV3. The ion is approximately 155Å away
from the viral center and forms a pentagonal bipyramid
structure with seven ligands. It interacts with the five sym-
metry-related main-chain carbonyl oxygens of Ser1141 at
an ion–ligand distance of 3.0Å. Two water molecules are
situated on the fivefold axis ‘above’ and ‘below’ the ion at a
distance of 2.3 and 3.7Å, respectively (‘above’ and ‘below’
indicate the direction toward the exterior and interior of the
virus, respectively). With the exception of the water mol-
ecule at 2.3Å, these liganding distances are far longer than
those observed for many other Ca2+-binding sites, showing
that the affinity of Ca2+ at this site is low. Nevertheless, the
presence of Ca2+ at this site is demonstrated in that similar
ions in HRV14 and HRV16 are EGTA chelatable [48].
These ions in rhinoviruses, as in many metalloproteins,
may play a role in regulation of stability. However, the loss
of the ion itself seems not to be enough to lead to viral dis-
assembly as no conformational changes were observed in
the EGTA-treated virus structures.
RNA structure
There is a weak (about 2s; see section on ‘Quality of the
HRV3 electron-density map’ for definition of s) plate-like
density near residue Trp2038 within the viral cavity. This
density is similar to that assigned as an RNA base in
HRV14 [49], HRV16 (AT Hadfield, RZ and MGR, unpub-
lished results), poliovirus [22] and coxsackievirus B3 [25].
It forms a stacking interaction with Trp2038. Residue 2038
is conserved in all rhinoviruses of known sequence and
may, therefore, be important in interacting with RNA and
may help RNA packaging. Site-directed mutagenesis of
this residue to alanine, valine or histidine in HRV16 is
lethal (W-M Lee, personal communication).
The site for receptor attachment in the canyon
Fourteen of the 18 residues in the footprint of ICAM-1 on
HRV14 are the same in HRV3. The four different residues
are away from the center of the ICAM-1 footprint (Fig. 5)
and expose one additional residue in HRV3. As a first
approximation, IC50 (the concentration of soluble ICAM-1
that inhibits 50% of the rhinovirus infectivity) of ICAM-1
for different rhinoviruses is reciprocally proportional to the
affinity constant of ICAM-1 to these viruses. The differ-
ence in IC50 between HRV3 (4.6±1.5mM) and HRV14
(3.3±0.5mM) [50] is not significant, indicating that the
above residues are not critical for ICAM-1 binding.
Conformation of WIN56291 when complexed with HRVs
The HRV3–WIN56291 complex (Fig. 6) shows continuous
electron density for most of the main-chain atoms. The
side chains are also mostly well defined. However, residues
1218, 1219 and 1220, in the GH loop that forms part of the
antiviral-binding pocket, have somewhat diffuse density
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Table 2
Comparison of VP4 and N termini of VP1 in several different picornaviruses.
HRV14 HRV3 HRV16 HRV1A Polio1 Polio3
Number of amino 289 288 285 287 302 302
acids in VP1
Regions of VP1 1014–1289 1016–1288 1001–1285 1005–1287 1006–1010 1007–1010
visible in the 1020–1302 1024–1302
electron-density map
Conformation of the disordered disordered 1001–1012 forms 1005–1012 forms 1006–1010 and 1007–1010 and
N terminus of VP1 an a helix which an a helix 4002–4006 form 4003–4006 form
interacts with the two parallel b strands two parallel
N terminus of VP4 b strands
Number of amino 68 68 68 68 68 68
acids in VP4
Regions of VP4 4029–4068 4026–4068 4001–4007 4026–4044 4002–4016* 4002–4016*
visible in the electron- 4023–4044 4023–4069 4023–4069
density map
Conformation of disordered disordered 4001–4007 and disordered 4003–4006 and 4003–4006 and
the N terminus 4023–4038 form 4027–4030 form 4027–4030 form
of VP4 two antiparallel two antiparallel two antiparallel
b strands b strands b strands
Myristate on VP4 disordered disordered ordered disordered ordered ordered
*4001 is the myristate attached to VP4.
(Fig. 6b). These residues also have diffuse densities in the
uncomplexed structures, suggesting that the GH loop is
rather flexible.
The density corresponding to the WIN56291 compound is
well defined (Fig. 6b). The oxazoline and phenoxy rings lie
in slightly flattened density and are coplanar. The two chlo-
rines on the phenoxy ring are seen as two large bulges. The
isoxazole ring at the other end of the molecule is almost
perpendicular to the plane of the phenoxy and oxazoline
rings. The conformation of WIN56291 and its position
within the HRV3 drug-binding pocket is essentially the
same as it is in HRV14 (Fig. 7a). The conformations and
binding sites of this compound in HRV16 and HRV1A have
greater similarity to each other than to those in HRV14 and
HRV3 (Fig. 7a). The principal difference in the drug con-
formation between HRV3 and HRV16 is the bend of the
aliphatic chain (Fig. 7a,b). Tyr1128 and Met1224 in HRV3
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Figure 4
Structure of the N terminus of VP1.
(a) Stereodiagram showing different
conformations of VP4 and the N termini of
VP1 in HRV14 (red), HRV16 (green) and
polio1 (black). Shown also are the radial
distances from the viral center along the
fivefold axis. The external surface of the virion
is at a radius of about 150 Å. (b) The N-
terminal residues of VP1 displayed on helical
wheels. Red, blue and black represent
hydrophilic, hydrophobic and glycine residues,
respectively. Residues in HRV1A or HRV3
which differ from those in HRV16 or HRV14
are shown in parenthesis. Residues
surrounding the HRV16 helical wheel are the
VP4 residues which interact with the VP1 helix
in HRV16. (c) Amino acid sequence alignment
of the N termini of VP1 in rhinoviruses.
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(corresponding to Ile1122 and Leu1217 in HRV16) cause a
bend at the second carbon atom (C2#) in the aliphatic chain
and the compound to be translated approximately 2Å
further into the pocket and about 1Å perpendicular to its
length. The translation further into the pocket in HRV3,
together with the smaller residue Cys1199 (compared 
with a methionine in HRV16) at the other end of the 
pocket, creates too much space for shorter compounds such
as WIN56291. This is consistent with the larger MIC50
(MIC50 is the minimum concentration of WIN compound
which inhibits 50% of the rhinovirus infectivity in cell
culture) values for WIN56291 in HRV3 compared with
HRV16 (Fig. 6c). Some drug-resistant mutants of HRV14,
selected in the presence of long WIN compounds (with
seven-carbon aliphatic chains), have Cys1199 replaced by
tyrosine or tryptophan [28], thus inhibiting drug entry into
the pocket. However, these mutants have less resistance to
shorter compounds, demonstrating the role of Cys1199 in
controlling compound length.
All of the group B rhinoviruses with known sequence have
similar amino acids forming the drug-binding pocket
(Table 3). Group B rhinoviruses contain small isoleucine,
valine or leucine residues in place of Tyr1128 or Met1224
in HRV3, but contain a bulky methionine residue in the
position of Cys1199. These three residues appear to be
the major determinants that control different preferred
lengths and conformations of antiviral compounds.
Polioviruses were also associated with group A by Andries
et al. [20]. However, residues comprising the pocket of
poliovirus not only differ from group B rhinoviruses, 
but also differ considerably from group A rhinoviruses
(Table 3). In spite of this, long compounds, such as
WIN51711, are preferred by polioviruses and bind in
similar conformations to those binding to group A rhi-
noviruses (Fig. 7c) [51]. Thus, common features must
exist in the pockets of rhinoviruses and polioviruses that
contribute to the similar drug lengths and conformations
preferred by these viruses. One important feature is the
existence of a large residue in all group A rhinoviruses
and polioviruses (tyrosine, phenylalanine or leucine) at
the position of 1128 in HRV14, whereas in group B the
corresponding residue is smaller (isoleucine or valine). In
group A viruses, this residue causes a kink in the aliphatic
chain of bound antiviral compounds, whereas in group B
viruses the drug binds in a relatively linear fashion. The
length of the drug may be controlled by a number of
factors common to polioviruses, HRV14 and HRV3. The
large residue (Tyr1128 in HRV14 and HRV3) will tend to
force the large aromatic portion of the drug further into
the available space of the pocket to avoid steric hin-
drance. The pore end of the pocket, determined in part
by residue 1199 (HRV14 and HRV3 numbers), is some-
what different between polioviruses and the group A rhi-
noviruses, but both sets of structures allow for fairly long
antiviral compounds.
Conformational changes of the virus induced by WIN56291
Antiviral compounds displace the naturally occurring
pocket factor in HRV16, HRV1A, coxsackievirus B3 and
polioviruses. This is particularly well demonstrated by the
electron-density map of coxsackievirus B3 complexed
with a compound shorter than the pocket factor, as there
is no trace of the pocket factor in those regions not occu-
pied by the compound. In the above-mentioned viruses,
the conformational changes produced by the displacement
of pocket factor are quite small, being mostly less than
1.2 Å [18].
In contrast, the conformational changes are much larger
when antiviral compounds bind to HRV3 or HRV14, which
have no pocket factor in the purified virus used for crystal-
lization and in which the pocket is collapsed. In these
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Figure 5
Footprint of the receptor on the viral surface.
(a) Diagrammatic view of the canyon and the
ICAM-1 footprint (shaded area). (b,c) Enlarged
views of residues in the ICAM-1 footprint on
HRV14 (b) and their corresponding residues
in HRV3 (c). Residues that differ between
HRV3 and HRV14 are shown as shaded areas
in (b) and (c).
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viruses, the antiviral compounds must enlarge the pocket’s
volume to permit entry. When WIN56291 binds to HRV3,
the largest changes occur in the GH loop, including
residues 1212–1225, where the Ca atom of 1217 moves
4.4Å. Other large conformational changes, with displace-
ments of Ca atoms as large as 0.9Å, occur between residues
1152–1157 in the EF loop and between residues 1103–1107
in the loop between the bC strand and the aA helix. Some
very minor changes that have less than 0.6Å displacement
of Ca atoms, although with uncertain significance, occur
between residues 1126–1129 in bD, 1186–1191 in bG, and
1197–1200 also in bG. The conformational changes that
occur when WIN56291 binds to HRV3 and HRV14 are
similar, consistent with the similar MIC50 values for this
compound in these two viruses (Fig. 6a).
The pocket and pocket factor
The crystal structures of HRV3 and HRV14, unlike other
rhinoviruses, polioviruses, bovine enterovirus and coxsack-
ievirus B3, do not contain pocket factors in their hydropho-
bic pockets. It has been proposed that there is a loosely
bound cellular pocket factor in HRV14, which is extracted
during the purification procedure [7,11]. Presumably, the
absence of the pocket factor in HRV3 and HRV14 is due
to differences in residues lining the pocket compared with
other rhinoviruses and polioviruses.
There are three kinds of pockets in rhinoviruses and
polioviruses, as represented by group B rhinoviruses,
group A rhinoviruses and group A polioviruses. Group B
rhinoviruses prefer short antiviral compounds and short
pocket factors. Both group A rhinoviruses and polioviruses
prefer long antiviral compounds, but group A polioviruses
contain long pocket factors, whereas group A rhinoviruses
do not contain any pocket factor. The position and confor-
mation of WIN compounds within the pocket mimics the
position and conformation of the respective pocket factor
in polioviruses and group B rhinoviruses (Fig. 7d). As WIN
compounds bind similarly in polioviruses and HRV14, and
as polioviruses contain a long pocket factor, it seems rea-
sonable that a long pocket factor would also be able to
bind in HRV14 or HRV3. However, a pocket factor is dif-
ferent from a WIN compound in that it has a much smaller
volume, as it does not have the ring structures at both ends
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Figure 6
Capsid-binding antiviral compounds.
(a) Structures of WIN56291, WIN51711 and
a sphingosine molecule. (b) Electron density
for the HRV3–WIN56291 complex showing
the flexible GH loop and the WIN compound
conformation. (c) MIC50 values for
WIN56291.
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of the molecule. Thus, it may be especially important to
have a narrow and hydrophobic pocket to maximize the
interaction between the virus and the pocket factor.
Polioviruses seem to form a better binding environment
for pocket factor than HRV14 or HRV3, according to this
criteria (Fig. 7e). In HRV14 or HRV3, residues His1245
and Ser1126 (Table 3) make the middle part of the pocket
broader and more polar than polioviruses, which is not the
most suitable binding environment for an aliphatic chain
[51]. Furthermore, in the region close to the pore, residues
Leu1106 and Met1221 in HRV14 or HRV3 are replaced
by either a tyrosine or a phenylalanine in all polioviruses.
These two aromatic residues in polioviruses (Table 3),
together with residues Phe1130 and Tyr1205, interact
extensively with atoms C3–C7 (Fig. 6a) of the sphingosine
pocket factor, which may also contribute to the favorable
binding of a pocket factor.
Sequence information [20,52,53] shows that rhinoviruses
belonging to the same antiviral group share significant
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Figure 7
Comparison of the binding mode of antiviral
compounds in different rhinoviruses. The
orientations of all parts of this figure are
identical and are illustrated in Figure 1.
(a) Different conformations of WIN56291 in
HRV3 (purple), HRV14 (red), HRV16 (green)
and HRV1A (yellow), and residues causing
these different conformations. The
conformation of a long compound,
WIN51711, in HRV14 is shown in black.
(b) Electron densities of WIN56291 in
HRV16 (top) and HRV3 (bottom)
superimposed with the WIN56291 structures
in HRV16 (thin line) and HRV3 (thick line),
demonstrating the bent conformation and
translation of WIN56291 in HRV3 compared
with HRV16. (c) Residues contributing to the
similar conformation of WIN51711 in polio3
(blue) compared with HRV14 (red). The
corresponding residues and the different
conformation of WIN56291 in HRV16 are
also shown (green). (d) Positions and
conformations of WIN56291 (green) and the
pocket factor (dark green) in HRV16, as well
as WIN51711 (light blue) and the pocket
factor (dark blue) in polio3, showing the
similar position and conformation between
pocket factors and WIN compounds.
(e) Residues important for binding pocket
factor in polio3 (blue) compared with the
structure of HRV14 (red) when complexed
with WIN51711.
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amino-acid sequence similarities, especially in the pocket
region (Table 3). Thus, group B rhinoviruses may all favor
the binding of a short pocket factor, while group A rhi-
noviruses are likely to bind loosely to a pocket factor as in
HRV14 and HRV3. On the other hand, polioviruses, having
a pocket different from either group A or group B rhi-
noviruses, favor the binding of a long pocket factor. 
The stability difference between HRV16 and HRV14 or HRV3 
HRV16 is more stable than both HRV3 and HRV14 when
treated with soluble ICAM-1 or at low pH [35]. The better
binding of a pocket factor and the interaction of VP4 with
the amphipathic helix at the N terminus of VP1 are stabi-
lizing factors in HRV16.
Andries et al. [20] noticed that viruses in antiviral group B
accounted for five times as many clinical colds as viruses
in group A. Taking into account that there are twice as
many viruses in group B as in group A, viruses in group B
still account for at least twice as many clinical infections as
those in group A. It was suggested that ‘something in the
structure of antiviral group B viruses endows them with a
higher pathogenicity’ [20]. As discussed earlier, viruses in
group B may all contain pocket factors and amphipathic
helices in the N termini of VP1, and both of these factors
contribute to the viral stability. This may permit group B
viruses to have a higher chance of successful transmission
from one host cell to another and lead to a higher patho-
genicity. 
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Table 3
Equivalent residues that line the antiviral-binding pocket in different picornaviruses.*
Group A HRV Group B HRV† Group A polio†
HRV14 or HRV3 HRV16 Nine other rhinoviruses‡ Polio1 Polio3
I1104 I1098 8I, 1V I1110 I1110
L1106 L1100 7L, 2I Y1112 Y1112
F1124§ F1118 9F F1130 F1130
S1126§ S1120 9S M1132 M1132
Y1128 I1122 9I L1134 F1134
A1150 Y1142 8Y, 1F I1157 I1157
Y1152 Y1144 9Y Y1159 Y1159
P1174 A1166 7A, 2M P1181 P1181
V1176 V1168 5V, 4I I1183 I1183
F1186 F1179 9F I1194 I1194
V1188 L1181 8L, 1I V1196 V1196
V1191 L1184 8L, 1M V1199 V1199
Y1197 Y1190 9Y Y1205 Y1205
C1199 M1192 9M H1207 H1207
N1219 N1212 9N N1235 D1236
M1221 M1214 9M F1237 F1238
M1224 L1217 6L, 3I L1240 L1241
H1245§ H1238 9H L1261 M1262
A3024 A3024 9A A3024 A3024
*The structure of HRV14 complexed with WIN51711 was used to
select these residues. †Bold type indicates residues that are different
from those of HRV14. ‡The nine group B rhinoviruses are HRV1A,
HRV1B, HRV2, HRV9, HRV15, HRV39, HRV49, HRV85 and HRV89.
Residues without ‘§’ have at least one atom located within 4.0 Å from
WIN51711. Note that residues A1150 and P1174 have only main-
chain atoms closer than 4.0 Å to WIN51711. Residues with ‘§’ were
selected because their equivalent residues in polio3 are in the vicinity
of either WIN51711 or the sphingosine pocket factor, although they
are at a distance greater than 4 Å from WIN51711 in HRV14.
Table 4
Percentage of amino acid sequence identity between different picornaviruses in the whole structural protein region  (above the
diagonal) and in the VP1 region (below the diagonal).
Antiviral group A Antiviral group B Antiviral group A
Virus HRV3 HRV14 HRV16 HRV1A Polio 1 Polio 3
HRV3 88 52 51 50 49
HRV14 85 52 51 50 50
HRV16 42 43 80 49 50
HRV1A 41 42 71 48 48
Polio 1 46 46 41 39 82
Polio 3 45 46 41 38 76
The evolution of rhinoviruses and polioviruses
HRV14 has long been considered an outlier among rhi-
noviruses based on sequence comparisons [52]. It was,
therefore, surprising to find that the amino-acid sequences
of the structural proteins in HRV3 and HRV14 were 88 %
identical. It is noteworthy that HRV14 and HRV3 both
belong to antiviral group A. Furthermore, the partial amino-
acid sequence (VP2 region) of another group A rhinovirus,
HRV72, has an identity greater than 84% with both HRV14
and HRV3 [53]. On the other hand, the VP2 sequences of
18 group B rhinoviruses, including HRV16 and HRV1A,
showed significant similarity (>70% sequence identity)
with each other, but considerable dissimilarity (< 60%
sequence identity) with rhinoviruses in group A [53].
Sequences for all the structural proteins of ten rhinoviruses
support the observation derived from the VP2 sequence
alone [20,52]. Polioviruses are also associated with antiviral
group A, based on their antiviral compound sensitivities,
but their amino-acid sequences not only differ from group
B rhinoviruses, but also differ considerably from group A
rhinoviruses (Table 4).
Various phylogenetic trees showing the relationships among
rhinoviruses and polioviruses have been computed based
on nucleotide or amino-acid sequences for various genes or
gene products [52,53]. The phylogenetic tree based on the
amino-acid sequence similarity in VP1 (which contains the
residues forming the drug-binding pocket; Fig. 8) demon-
strates the separate development of antiviral groups A and
B in rhinoviruses and polioviruses. However, the analysis 
of the phylogenetic trees, derived from VP1, VP2 or the
whole structural protein region, does not lead to a clear con-
clusion on the origin of the major- and minor-receptor group
rhinoviruses. It appears that the use of specific receptors
may have evolved more than once.
Biological implications
The more than 100 serotypes of human rhinovirus
(common cold virus; HRV) can be divided into a major
and a minor group based on their use of different recep-
tors. HRV14, HRV3 and HRV16 all belong to the
major-receptor group, which uses ICAM-1 as a receptor,
whereas HRV1A belongs to the minor-receptor group.
HRVs can also be divided into two groups (A and B)
based on their sensitivity to a series of capsid-binding
antiviral compounds. HRV14 and HRV3 belong to group
A, whereas HRV16 and HRV1A belong to group B.
Human rhinovirus 3 (HRV3) was chosen for structural
investigations because it is one of a subset of serotypes
that best represented the drug sensitivity of most 
rhinoviruses. It was surprising to find that the sequence
and structure of HRV3 was very similar to HRV14, as
the latter serotype had previously been found to be an
outlier among rhinoviruses. Furthermore, HRV3, like
HRV14, but in contrast to all other known structures of
HRVs, polioviruses, bovine enterovirus and coxsack-
ievirus B3, did not contain a ‘pocket factor’ bound
within the VP1 b barrel. The pocket factor binds into
the same pocket used by the capsid-binding antiviral
compounds. It has been suggested that the pocket factor,
presumably of cellular origin, regulates the viral life
cycle, but its absence in HRV3 and HRV14 indicates
that the weakly binding pocket factor may have been
removed during purification. Antiviral compounds can
displace the pocket factor, thereby interfering in cell
attachment or uncoating. 
The division of HRVs into major- and minor-receptor
groups does not correlate well with sequence or struc-
tural similarities. For instance, the major-receptor group
1216 Structure 1996, Vol 4 No 10
Figure 8
A phylogenetic tree for rhinoviruses and
polioviruses based on amino acid sequence
similarities in VP1. Distances between
different viruses were calculated using the
UWGCG (University of Wisconsin Genetics
Computer Group) DISTANCES program.
Besides viruses with known structure, two
more rhinovirus serotypes (HRV2 and HRV89)
were used in the phylogenetic tree to
demonstrate that the use of specific receptors
by rhinoviruses may have had a number of
independent origins.
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rhinovirus HRV16 has more in common with the minor
group rhinovirus HRV1A than with the major group rhi-
noviruses HRV3 and HRV14. On the other hand, group-
ing of HRVs by their drug sensitivity does correlate with
sequence and structural similarities. Both HRV3 and
HRV14 belong to antiviral group A, whereas HRV1A
and HRV16 belong to group B. 
Although all polioviruses belong to antiviral group A,
purified and crystallized polioviruses invariably contain
well bound pocket factor unlike HRV3 and HRV14.
Comparison of the binding mode of antiviral compounds
to these viruses shows considerable similarity in the con-
formation and position of the compounds. Thus, it is rea-
sonable to assume that a putative pocket factor would
bind in HRV3 and HRV14 as it would in polioviruses.
However, the environment of the pocket factor in group
A rhinoviruses provides poorer hydrophobic interac-
tions compared with polioviruses, explaining the absence
of pocket factor in the available structures of group A
rhinoviruses.
HRV3, like HRV14, has the first 12 amino acids of
VP1 disordered, whereas in the group B rhinoviruses
this polyprotein forms an amphipathic helix which inter-
acts with VP4. The greater stability of the group B rhi-
noviruses in the presence of soluble ICAM-1 or at low
pH may result from the stabilizing effects of the amphi-
pathic VP1 helix and the presence of a better bound
pocket factor. This higher stability of group B rhi-
noviruses also correlates with their higher pathogenic-
ity, permitting greater success in transmission from host
to host. 
Materials and methods
Virus growth, purification and crystallization
HeLa cells were grown in a suspension culture to a concentration of
6–8 ×105 cells ml–1. Ten to twelve liters of HeLa cells were harvested
by centrifugation at 1600 rpm for 10 min. The pellet was suspended in
3150 ml of medium A (see [54]) plus 350 ml of 10 % calf serum. The
cells were then distributed evenly among 20 sterilized roller bottles and
monolayers formed in 3–5 h. Each bottle was washed with 10–20 ml of
PBS buffer and was infected with approximately 9 × 108 PFU of HRV3.
10 ml of AH medium (5.94 g Hepes dissolved in medium A) was then
added to each bottle. After 1–2 h of viral attachment, 2.5 ml of both calf
serum and AH medium were added to bring the final volume to 50 ml.
Bottles were then rolled slowly at 35° C until complete cytopathic
effects were observed (≈24 h).
The infected cells were frozen and thawed three times and homogenized
twice. The suspension was spun at 10 K rpm at 5°C for 10min. PEG
8000 and NaCl were added to the supernatant to achieve a final con-
centration of 8% (w/v) and 0.5M, respectively. The solution was incu-
bated overnight at 4°C to precipitate the virus. The virus was harvested
by spinning at 10K rpm at 5°C for 15min. The pellet was re-suspended
in 30–45ml of cold 0.25M Hepes/0.75M NaCl/pH7.2 buffer, and was
treated with MgCl2 (0.005M) and DNase (0.01mgml–1) for 30min at
room temperature, followed by 1 mgml–1 trypsin treatment at 35° C for
10min to inactivate the DNase. After 0.01 M NaEDTA (pH9.5) and 1%
sarcosine were added, supernatants were collected following centrifu-
gation at 12K rpm for 10min at 5°C and then centrifuged through a
30% sucrose cushion at 48K rpm at 5°C for 2h. The pellet was resus-
pended and spun through a 10 –40% potassium tartrate gradient at
36K rpm at 5°C for 90min. The resulting virus band was collected and
the concentration of the virus was measured by a spectrophotometer
using an absorption coefficient of 7.7 ml (mg × cm)–1 at 260nm wave-
length. The virus was brought to a final concentration of 10 mgml–1 in
preparation for crystallization.
The hanging drop vapor diffusion method was used to crystallize
HRV3. The reservoir solution contained 10 mM CaCl2 and 0.75 % PEG
8000 in a 0.25 M Hepes/0.75 M NaCl/pH 7.2 buffer. The hanging drop
contained 5 ml of 10 mg ml–1 virus mixed with 5 ml of reservoir solution.
The WIN56291 compound was diffused into HRV3 crystals that had
been transferred to 500ml of stabilization buffer, which was the same as
the reservoir solution used in crystallization, except that the PEG 8000
concentration had been increased to 4%. The WIN56291 compound
was then dissolved in DMSO to a concentration of 10mgml–1. 40ml of
this solution was added to the stabilization buffer that contained the crys-
tals. The crystals were allowed to equilibrate with the WIN compound for
at least 24h before data collection.
Determination of amino-acid sequence of capsid proteins for
HRV3
The HRV3 genomic RNA was isolated from purified virions using Pro-
teinase K digestion and phenol:chloroform extraction. The 5′ portion of
the genomic RNA, covering the viral capsid region, was reverse tran-
scribed to cDNA using Moloney murine leukemia virus (M-MuLV)
reverse transcriptase and the primer 5′-GAAATCTTATTAGCAATC-
CATTC-3′. The resultant cDNA was amplified using the polymerase
chain reaction (PCR) and was cloned into the plasmid vector pCRII
using the ‘TA’ cloning kit (Invitrogen). The two primers used in DNA
amplification were 5′-TAGTTTGGTCGATGAGGCTAGGAATTCCC-3′
and 5′-ATCCCACCACAGTCTCCTGGTTCTGCTGGT-3′. A clone that
contained the entire capsid coding region was selected by checking
the size of the insert and sequencing both ends. Subclones carrying
various lengths of the insert were generated from this clone using the
‘Erase-a-Base’ system (Promega). The two restriction enzymes used to
generate the ‘substrate’ and ‘protection’ sites in the ‘Erase-a-Base’
system were NdeI and KpnI, respectively. These subclones were
sequenced using the dideoxynucleotide sequencing method [55], and
the sequence information was assembled based on the alignment with
HRV14 cDNA sequence using the program library of the University of
Wisconsin Genetics Computer Group (UWGCG). The remaining gaps
between subclones were filled in using primers designed from known
sequences. The nucleotide sequence was then translated into the
equivalent amino-acid sequence. The nucleotide and amino-acid
sequences for the capsid region of HRV3 were found to be 77% and
88 % identical, respectively, to HRV14.
Diffraction data collection and processing
The complete HRV3 data set was collected on imaging plates at the
F1 station of the Cornell High Energy Synchrotron Source (CHESS) in
a single data trip. The wavelength of the F1 station was approximately
0.91 Å. Oscillation angles were chosen to be 0.35° or 0.40° to avoid
overlap of reflections at high resolution. The crystal-to-imaging plate
distance was 300 mm and the exposure time was about 60 sec. The
HRV3 crystals diffracted to 2.8 Å resolution, although the diffraction
data were used only to 3.0 Å resolution for the structure solution due to
the poor quality of the data at higher resolution. Six to twelve useful
exposures could be taken from each crystal before the diffraction
showed signs of deterioration.
The imaging plates were indexed using S Kim’s auto-indexing
program [56]. The cell parameters from different crystals were aver-
aged and used to obtain integrated intensities [57]. Post-refinement
[58] was used to refine crystal orientations, cell dimensions and
crystal mosaicity. The statistics of the refined data set are given in
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Table 5. The cell dimensions after post-refinement were a = 400.8,
b = 344.2, c = 303.9 Å, a = b =g = 90°, assuming a wavelength of
0.9100 Å.
Space group and structure determination
The indexing program [56] showed HRV3 had a primitive cell with
angles close to 90°. The HRV3 crystals were also shown to have mmm
symmetry in reciprocal space. Hence, the only possible orthorhombic
space groups were P222, P2221 (or P2122 or P2212), P21212 (or
P22121 or P21221) and P212121. Two particles per unit cell gave a rea-
sonable VM value of 2.5 Å3 Da–1 [59]. Thus, space group P212121 could
be ruled out. Furthermore, only space group P21212 (or P22121 or
P21221) could accommodate two viral particle with diameters around
300 Å in one unit cell. For example, in space group P21212 the particles
would be placed on twofold axes close to (0,0,¼) and (½,½,¾) to
reach a maximum separation of 304 Å. 
As there were only two particles in the unit cell, the rotation and transla-
tion problem was simplified into a search for the rotation about the crys-
tallographic twofold axis and translation along this axis. A self-rotation
function [60] for k = 72°, 120° and 180° was calculated with 8 – 10 Å
resolution data and a 150 Å radius of integration. This showed peaks
corresponding to only one icosahedral particle, suggesting that the two
particles in the unit cell had a very similar, if not exactly the same, orien-
tation. However, when 3.0–3.2 Å resolution data were used for the rota-
tion function, one threefold peak showed an approximate 1° split
representing a rotation about the b axis. Thus, the two particles in the
unit cell were related to a particle in the standard orientation by a rota-
tion of 89.5° and 90.5° about a direction parallel to b. As the splitting
was about the b axis, the twofold axis must be along b and the correct
space group was, therefore, identified as P21221.
A stepwise R factor search using 10–8.5 Å resolution data, the previ-
ously determined particle orientations and HRV14 as a search model,
showed that the two particles were situated at the (0, 0.2510, 0) and
(0.5000, 0.7490, 0.5000) positions. This arrangement would lead to a
pseudo I222 symmetry, which was confirmed by the systematic weak-
ness of the h + k + l = odd reflections.
The orientation and position of one independent HRV3 particle were
refined with the program CLIMB (MGR, unpublished data) using a
4.0 Å HRV14 map. CLIMB minimizes the density differences between
icosahedral symmetry-related points by systematically altering the posi-
tional and orientational parameters to optimize the particle orientation
and position. Only the rotation angle k about the b axis and the transla-
tion along the b axis were refined. After four cycles of refinement, the
orientation and position converged to (f = 0°, ψ = 0°, k = 89.34°) and
(0, 0.2504, 0), respectively.
A 30 Å to 4.0 Å resolution map was calculated using the program
ENVELOPE with HRV14 as a phasing model [61]. The map was aver-
aged within a spherical mask that had outer and inner radii of 165Å and
70 Å, respectively. The outside and inside of this mask were considered
as solvent and nucleic acid, respectively, and were set to their mean
values. Overlapping particles were separated by tangential planes. The
overall correlation coefficient improved from 0.605 to 0.858 after five
cycles of averaging.
Resolution of the electron-density map was extended to 3.5 Å using
phases from 30Å to 4.2Å obtained from the back-transformed averaged
map and phases from 4.2Å to 3.5Å obtained from the known HRV14
model. The resultant map was averaged and solvent flattened using the
same spherical mask as had been used for the 30 Å to 4.0Å map. The
overall correlation coefficient improved from 0.8561 to 0.9100 after six
cycles of averaging.
The 30Å to 3.5Å map was further extended to 3.0Å using the same
strategy. Phases for 30 to 3.6Å data were obtained from averaging, and
phases from 3.6 to 3.0Å were obtained from the HRV14 model. After
eight cycles of averaging and solvent flattening, the overall correlation
coefficient improved from 0.846 to 0.880.
Pseudo higher order space groups are not uncommon for icosahedral
virus crystals [62–64]. In these circumstances, the quality of phasing of
the ‘odd’ (weak) reflections is very sensitive to correct determination of
the orientational and positional parameters. Indeed, a wrong determina-
tion of space group or inaccurate parameter determination results in
very poor correlation coefficients for ‘odd’ reflections without affecting
significantly the ‘even’ reflections. The correctness of the current struc-
ture determination is, therefore, indicated by the 0.93 and 0.84 correla-
tion coefficients for the h+k+ l =2n and 2n+1 reflections, respectively,
between 30 Å and 8 Å resolution [49].
Wavelength adjustment and preliminary refinement
The amino acids of HRV3 capsid proteins were built into the map using
the graphics program O [65]. The model of the HRV3 structure was
found to be systematically expanded with respect to the corresponding
2.4 Å resolution refined HRV14 structure (B Berger and MGR, unpub-
lished results) as shown by plots of differences in the x,y,z coordinates
as a function of the mean value of x, y or z, respectively (Fig. 9). Similar
plots comparing HRV1A and HRV14 gave no significant differences.
The correct cell dimensions of cubic HRV14 had been established
using CuKa radiation [49]. Apparently, the bond lengths of HRV3 were
systematically larger than those of HRV14. A possible explanation for
this phenomenon was that the wavelength used for processing the
HRV3 data was bigger than it should have been due to the inaccuracy
of the synchrotron X-ray wavelength determination. This would imply
that the cell dimensions determined by post-refinement, assuming a
wavelength of 0.9100 Å, were 1.007 times too big, as suggested by
the slope of the curve in Figure 9. Hence, the cell dimensions were cor-
rected to a = 397.9, b = 341.8, c = 301.7 Å and these were used for
further refinement. Lea et al. [66] and Curry et al. [67] have used similar
procedures to calibrate the wavelength of the synchrotron radiation.
A preliminary refinement of HRV3 coordinates was performed using the
energy minimization routine of the program X-PLOR [68]. For 5.0–3.0 Å
resolution data, the final R factor calculated using the refined coordi-
nates with an overall B factor of 15 Å2 was 28.1 %. The rms deviations
from the ideal bond lengths and bond angles were 0.009 Å and 1.8°,
respectively. Rfree is not a useful indicator in the presence of high 
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Table 5
Statistics on the diffraction data of native HRV3.*
Resolution (Å) 30–25 25–12.5 12.5–8.33 8.33–6.25 6.25–5.00 5.00–4.17 4.17–3.57 3.57–3.12 3.12–2.80
No. of reflections 430 8074 24 206 45 589 75 728 112 936 147 856 176 196 139 901
Data (%) 73 82 91 88 88 89 82 73 47
Rmerge 7.42 9.75 9.31 11.81 11.37 10.11 11.96 14.89 18.90
*Number of imaging plates, 331; number of crystals, 45; cutoff
criteria = Fh2 > 3 s(Fh2); number of measurements, 1 917 753; number
of unique reflections, 730 925; overall completeness, 73.1 %; overall
Rmerge, 12.0 %.
non-crystallographic symmetry, because of the interdependence of
structure factors [69].
Structure determination of HRV3 complexed with WIN56291
An electron-density map was calculated with Fourier coefficient
(FD–kFN) ωN exp(iaN) [16]. FD and FN are the structure factor ampli-
tudes of the drug–virus complex and of the native virus placed onto the
same relative scale, respectively; aN is the phase for the native struc-
ture obtained from the molecular replacement and real-space averaging
procedure; ωN is the weighting factor dependent on the consistency
between the FN(obs) and FN(calc) obtained in the averaging procedure
used to determine phases of the native structure; and k is a suitably
chosen scale factor. A simple difference map with k = 1 was calculated
to locate conformational changes due to the drug binding to HRV3. A
map with k = 0.7 was calculated to interpret the actual drug and protein
conformations in the virus–drug complex. In this map, the density level
of the drug was similar to the density level of the surrounding protein
and the effects of the incomplete substitution and phase bias toward
native structure were minimized. The difference map was averaged
using the 30-fold noncrystallographic redundancy in HRV3 crystals
[61]. An atomic model was built into the averaged map using the
graphics program O [65]. The coordinates of this model were also
shrunk as discussed in the section on ‘Wavelength adjustment and 
preliminary refinement’.
Accession numbers
The coordinates have been deposited with the Brookhaven Protein Data Bank
(code 1RHI). The cDNA sequence has been deposited with the Gene Bank
(accession number U60874).
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Figure 9
Relationship between the Ca-coordinate differences (HRV3–HRV14)
and the coordinates of these atoms, prior to wavelength adjustment.
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